Adding Cadonilimab to First-Line Standard Chemotherapy Significantly Improves PFS and OS in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer By Ogkologos - November 15, 2024 719 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the COMPASSION-16 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR March is Multiple Myeloma Action Month March 29, 2022 EMA Recommends Granting a Conditional Marketing Authorisation for Amivantamab October 29, 2021 FDA Approval of KRAS Inhibitor Sotorasib for Lung Cancer Hailed as... June 25, 2021 Time to take on 9 new Cancer Grand Challenges March 8, 2023 Load more HOT NEWS Targeted Therapy for Treating Advanced Gastrointestinal Stromal Tumors (GISTs): The ASCO... Foodie Fridays-Gazpacho: A Favorite Summer Soup Adjuvant fractionated radiotherapy significantly improves DFS in patients with atypical meningioma... Pharmacokinetic and Pharmacodynamic Interactions Between Anticancer and Antiviral Drugs
